Centessa Pharmaceuticals plc
CNTA
$11.70
-$1.36-10.41%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 6.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 6.85M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 6.85M |
| SG&A Expenses | 13.71M | 12.50M | 11.17M | 13.44M | 12.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.58M | 46.41M | 43.98M | 36.09M | 42.03M |
| Operating Income | -74.58M | -46.41M | -43.98M | -36.09M | -35.18M |
| Income Before Tax | -110.28M | -41.96M | -43.11M | -37.57M | -35.69M |
| Income Tax Expenses | 1.05M | 608.00K | 705.00K | 481.00K | 1.14M |
| Earnings from Continuing Operations | -111.33M | -42.57M | -43.82M | -38.05M | -36.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -111.33M | -42.57M | -43.82M | -38.05M | -36.84M |
| EBIT | -74.58M | -46.41M | -43.98M | -36.09M | -35.18M |
| EBITDA | -74.49M | -46.32M | -43.90M | -36.00M | -35.08M |
| EPS Basic | -0.84 | -0.37 | -0.40 | -0.38 | -0.38 |
| Normalized Basic EPS | -0.36 | -0.23 | -0.25 | -0.23 | -0.22 |
| EPS Diluted | -0.84 | -0.37 | -0.40 | -0.38 | -0.38 |
| Normalized Diluted EPS | -0.36 | -0.23 | -0.25 | -0.23 | -0.22 |
| Average Basic Shares Outstanding | 132.05M | 116.25M | 109.49M | 99.89M | 97.92M |
| Average Diluted Shares Outstanding | 132.05M | 116.25M | 109.49M | 99.89M | 97.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
